Richard Larson
Section of Hematology / Oncology
Professor of Medicine
Director of the Hematologic Malignancies Clinical Research Program
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
AB1972Dartmouth CollegeChemistry
MS1973University of CambridgeNatural Science
MD1977Stanford University 
Residency1980The University of ChicagoInternal Medicine
Fellowship1983The University of ChicagoHematology/Oncology

Academic Interests

Dr. Larson’s academic interests include clinical trials in hematologic malignancies and stem cell transplantation, the determinants of response to therapy in leukemia and myelodysplastic syndromes and the etiology of therapy-related leukemias. He is chair of the Leukemia Committee of the Cancer and Leukemia Group B, a multicenter organization funded by the National Cancer Institute to conduct clinical trials in leukemia and other cancers.


Clinical Interests

Leukemia, lymphoma, Hodgkins Disease, myelodysplastic syndrome, stem cell transplantation, acute and chronic leukemias.


Representative Publications

  1. Richard A. Larson, Marc Boogaerts, Elihu Estey, Chatchada Karanes, Edward A. Stadtmauer, Eric L. Sievers, Philippe Mineur, John M. Bennett, Mark S. Berger, Catharine B. Eten, Mihaela Munteanu, Michael R. Loken, Jacques J. M. van Dongen, Irwin D. Bernstein, and Frederick R. Appelbaum for the Mylotarg Study Group. “Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).” Leukemia 2002; 16: 1627-1636.
  2. John C. Byrd, Krzysztof Mrozek, Richard K. Dodge, Andrew J. Carroll, Colin G. Edwards, Diane C. Arthur, Mark J. Pettenati, Shivanand R. Patil, Kathleen W. Rao, Michael S. Watson, Prasad R. K. Koduru, Joseph O. Moore, Richard M. Stone, Robert J. Mayer, Eric J. Feldman, Frederick R. Davey, Charles A. Schiffer, Richard A. Larson, and Clara D. Bloomfield. “Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse and overall survival in adult patients with de novo acute myeloid leukemia: Results from CALGB 8461.” BLOOD 2002; 100: 4325-36.
  3. John C. Byrd, Bercedis L. Peterson, Vicky Morrison, Kathy Park, Robert Jacobson, James W. Vardiman, Eva Hoke, Kanti Rai, Charles A. Schiffer, Richard A. Larson. “Randomized phase 2 study of fludarabine with concurrent versus sequential rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712.” BLOOD 2003; 101: 6-14.
  4. Stephen G. O’Brien, Francois Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy Hughes, Klaus Lechner, Johan L. Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John Shepherd, Bengt Simonsson, Alois Gratwohl, John M. Goldman, Hagop Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, and Brian J. Druker. “Interferon and low-dose cytarabine compared with imatinib for newly diagnosed chromic-phase chronic myeloid leukemia.” N Engl J Med 2003; 348: 994-1004.
  5. Sonali M. Smith, Michelle M. Le Beau, Dezheng Huo, Theodore Karrison, Ronald M. Sobecks, John Anastasi, James W. Vardiman, Janet D. Rowley, and Richard A. Larson. “Clinical-Cytogenetic Associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.” BLOOD 2003; 102: 43-52.



More Information

For more information about Dr. Richard Larson publications and research collaborations , please click here